17 - References

References

664 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 References

1. Sink KM, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-­term functional and cognitive outcomes. J Am Geriatr Soc 2008; 56:847–853.
2. Ruxton K, et al. Drugs with anticholinergic effects and cognitive impairment, falls and all-­cause mortality in older adults: a systematic review and meta-­analysis. Br J Clin Pharmacol 2015; 80:209–220.
3. Sunderland T, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-­matched controls. A dose-­response study. Arch Gen Psychiatry 1987; 44:418–426.
4. Fox C, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011; 59:1477–1483.
5. Bishara D, et al. The anticholinergic effect on cognition (AEC) scale – associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. Int J Geriatr Psychiatry 2020; 35:1069–1077.
6. Bishara D, et  al. Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. Int J Geriatr Psychiatry 2017; 32:650–656.
7. Wagg A. The cognitive burden of anticholinergics in the elderly – implications for the treatment of overactive bladder. Eur Urol Rev 2012; 7:42–49.
8. Pagoria D, et al. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep 2011; 12:351–357.
9. Womack KB, et al. Tolterodine and memory: dry but forgetful. Arch Neurol 2003; 60:771–773.
10. Tsao JW, et al. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349:2274–2275. Table 6.5  (Continued ) Condition Drug class or drug name Drugs to avoid in dementia Recommended drugs in dementia Other GI conditions Antispasmodics Atropine sulphate Dicycloverine hydrochloride Alverine, mebeverine, peppermint oil Hyoscine-­n-­butylbromide Propantheline bromide Pain Analgesics Pethidine Pentazocine Dextropropoxyphene Codeine Tramadol Methadone Paracetamol Oxycodone Buprenorphine Topical NSAIDs (where appropriate) Fentanyl patches (caution in opioid-­naïve patients) Morphine (may be indicated in treatment-­resistant pain or palliative care; use cautiously due to associated cognitive and other adverse effects) Urinary frequency Anticholinergic drugs used in overactive bladder Oxybutynin Tolterodine Fesoterodine Darifenacin Trospium Solifenacin (use if others are not available; some reports of cognitive adverse effects) Data for fesoterodine are still lacking; it is non-­selective, has high central anticholinergic activity but theoretically has very low ability to cross the BBB. Urinary retention Alpha blockers Not known to have effects on cognitive function. BBB, blood–brain barrier; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal.

Prescribing in older people CHAPTER 6 11. Edwards KR, et  al. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002; 50:1165–1166. 12. Kay G, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50:317–326. 13. Lipton RB, et al. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173:493–498. 14. Chancellor MB, et al. Blood-­brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging 2012; 29:259–273. 15. Park JW. The effect of solifenacin on cognitive function following stroke. Dement Geriatr Cogn Dis Extra 2013; 3:143–147. 16. Liabeuf S, et  al. Trospium chloride for overactive bladder may induce central nervous system adverse events. Eur Geriatr Med 2014; 5:220–224. 17. Isik AT, et al. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009; 13:672–676. 18. Geller EJ, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg 2017; 23:118–123. 19. Heesakkers J, et al. Safety and tolerability of fesoterodine in older adult patients with overactive bladder. Can Geriatr J 2022; 25:72–78. 20. Wagg A. Fesoterodine fumarate for the treatment of overactive bladder in the elderly – a review of the latest clinical data. Clin Investig 2012; 2:825–833. 21. Yonguc T, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson’s disease. World J Urol 2020; 38:2013–2019. 22. Joint Formulary Committee. British National Formulary (online). London: BMJ and Pharmaceutical Press; http://www.medicinescomplete.com. 23. Mahdy AM, et al. Histamine and antihistamines. Anaesth Intens Care Med 2011; 12:324–329. 24. Roy-­Desruisseaux J, et al. Domperidone-­induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. Ann Pharmacother 2011; 45:e51. 25. Medicines and Healthcare products Regulatory Agency. Domperidone: risks of cardiac side effects – indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use. 2014; http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON418518. 26. Bentley KR, et al. Therapeutic potential of serotonin 5-­HT3 antagonists in neuropsychiatric disorders. CNS Drugs 1995; 3:363–392. 27. Gridelli C. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. Drugs Aging 2004; 21:825–832. 28. Flicker C, et al. Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl) 1992; 107:437–441. 29. Ebert U, et  al. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 1998; 28:944–949. 30. Sanofi. Summary of product characteristics. Buscopan 10 mg tablets. 2020 (last updated November 2021); https://www.medicines.org.uk/ emc/medicine/30089. 31. Gupta P, et al. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging 2008; 25:415–443. 32. Ramsdell JW, et al. Effects of theophylline and ipratropium on cognition in elderly patients with chronic obstructive pulmonary disease. Ann Allergy Asthma Immunol 1996; 76:335–340. 33. Fritze J, et al. Pirenzepine for clozapine-­induced hypersalivation. Lancet 1995; 346:1034. 34. Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008 – present). Expert Opin Ther Pat 2012; 22:871–886. 35. Gray SL, et al. Drug-­induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 1999; 21:101–122. 36. Bailey RB, et al. Chronic salicylate intoxication. A common cause of morbidity in the elderly. J Am Geriatr Soc 1989; 37:556–561. 37. Hoppmann RA, et al. Central nervous system side effects of nonsteroidal anti-­inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991; 151:1309–1313. 38. Wysenbeek AJ, et al. Assessment of cognitive function in elderly patients treated with naproxen. A prospective study. Clin Exp Rheumatol 1988; 6:399–400. 39. Bruce-­Jones PN, et al. Indomethacin and cognitive function in healthy elderly volunteers. Br J Clin Pharmacol 1994; 38:45–51. 40. Barber JB, et al. Treatment of chronic non-­malignant pain in the elderly: safety considerations. Drug Saf 2009; 32:457–474. 41. Ripamonti C, et al. CNS adverse effects of opioids in cancer patients. CNS Drugs 1997; 8:21–37. 42. Alagiakrishnan K, et al. An approach to drug induced delirium in the elderly. Postgrad Med J 2004; 80:388–393. 43. McLachlan AJ, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. Br J Clin Pharmacol 2011; 71:351–364. 44. Dosa DM, et al. Frequency of long-­acting opioid analgesic initiation in opioid-­naive nursing home residents. J Pain Symptom Manage 2009; 38:515–521. 45. Tannenbaum C, et al. A systematic review of amnestic and non-­amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29:639–658. 46. McGuinness B, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev 2014; 7:CD007514. 47. Wagstaff LR, et  al. Statin-­associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23:871–880. 48. Zhou Z, et al. Effect of statin therapy on cognitive decline and incident dementia in older adults. J Am Coll Cardiol 2021; 77:3145–3156. 49. McGuinness B, et al. Statins for the prevention of dementia. Cochrane Database Syst Rev 2016; 1:CD003160. 50. Olmastroni E, et al. Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-­analysis of observational studies. Eur J Prev Cardiol 2022; 29:804–814.

666 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 51. Qiu C, et al. The age-­dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4:487–499. 52. Wändell P, et al. Antihypertensive drugs and relevant cardiovascular pharmacotherapies and the risk of incident dementia in patients with atrial fibrillation. Int J Cardiol 2018; 272:149–154. 53. Levi MN, et  al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-­analysis. J Hypertens 2013; 31:1073–1082. 54. Branco DR, et al. Direct oral anticoagulants vs vitamin K antagonist on dementia risk in atrial fibrillation: systematic review with meta-­analysis. J Thromb Thrombolysis 2023; 56:474–484. 55. Eisendrath SJ, et al. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987; 144:506–507. 56. Brezis M, et al. Nightmares from digoxin. Ann Intern Med 1980; 93:639–640. 57. Laudisio A, et al. Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey. Drugs Aging 2009; 26:103–112. 58. Athwal H, et al. Amiodarone-­induced delirium. Am J Geriatr Psychiatry 2003; 11:696–697. 59. Foley KT, et al. Separate episodes of delirium associated with levetiracetam and amiodarone treatment in an elderly woman. Am J Geriatr Pharmacother 2010; 8:170–174. 60. Cantu TG, et al. Central nervous system reactions to histamine-­2 receptor blockers. Ann Intern Med 1991; 114:1027–1034. 61. Gomm W, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neuroly 2016; 73:410–416. 62. Goldstein FC, et al. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc 2017; 65:1969–1974. 63. Lochhead P, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology 2017; 153:971–979.e974. 64. Haenisch B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015; 265:419–428. 65. Cooksey R, et al. Proton pump inhibitors and dementia risk: evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One 2020; 15:e0237676. 66. Grahl JJ, et al. Antimicrobial exposure and the risk of delirium in critically ill patients. Crit Care 2018; 22:337. 67. Bhattacharyya S, et al. Antibiotic-­associated encephalopathy. Neurology 2016; 86:963–971. 68. Kass JS, et al. Nervous system effects of antituberculosis therapy. CNS Drugs 2010; 24:655–667. 69. Bishara D, et al. Safe prescribing of physical health medication in patients with dementia. Int J Geriatr Psychiatry 2014; 29:1230–1241.